Senti Biosciences is trading at $0.16, down 5.83%, amid uncertainty following its October 21 merger, disclosed October 26. - The merger divested Senti’s former operating businesses; potential shareholder CVR payments depend on future milestones. - Senti raised about $2.5 million and said it may be unable to sustain operations as early as Q4 2026. - Major indexes were little changed; no October 27 announcement directly linking the intraday decline to a new catalyst was found.